NAVITRUX
AVYXA HOLDINGS · FOSAPREPITANT DIMEGLUMINE
Open FDA's page for this record- Application number
- NDA220436
- Sponsor name
- AVYXA HOLDINGS
- Submissions
- Submission type
- ORIG
- Submission number
- 1
- Submission status
- AP
- Submission status date
- 20260624
- Review priority
- STANDARD
- Submission class code
- TYPE 5
- Submission class code description
- Type 5 - New Formulation or New Manufacturer
- Application docs
- ID
- 86357
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220436Orig1s000ltr.pdf
- Date
- 20260626
- Type
- Letter
- ID
- 86384
- Url
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220436Orig1s000lbl.pdf
- Date
- 20260629
- Type
- Label
- Products
- Product number
- 001
- Reference drug
- Yes
- Brand name
- NAVITRUX
- Reference standard
- Yes
- Dosage form
- POWDER
- Route
- INTRAVENOUS
- Marketing status
- Prescription
- Active ingredients
- Name
- FOSAPREPITANT DIMEGLUMINE
- Strength
- EQ 150MG BASE/VIAL
- Harmonized identifiers (openFDA)
- Application number
- NDA220436
- Brand name
- NAVITRUX
- Generic name
- FOSAPREPITANT
- Manufacturer name
- AVYXA Pharma, LLC
- Product NDC
- 83831-153
- Product type
- HUMAN PRESCRIPTION DRUG
- Route
- INTRAVENOUS
- Substance name
- FOSAPREPITANT DIMEGLUMINE
- RxCUI
- 1731077, 2745874
- SPL ID
- bc79f63b-8a05-41b5-a349-f71f1313e791
- SPL set ID
- a41b7c3a-1376-43a7-b5b9-6ba2eba1e169
- Package NDC
- 83831-153-01
- UNII
- D35FM8T64X
